IRADIMED CORPORATION Financials IRADIMED CORPORATION
Equities
IRMD
US46266A1097
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.86 USD | +0.94% |
|
+2.10% | -11.82% |
| Apr. 03 | IRadimed Files $75 Million Common Stock Shelf Registration | MT |
| Feb. 08 | Transcript : IRadimed Corporation, Q4 2023 Earnings Call, Feb 08, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 268.5 | 279.7 | 570.3 | 355.5 | 598.4 | 530.1 | - |
| Enterprise Value (EV) 1 | 268.5 | 279.7 | 570.3 | 355.5 | 598.4 | 530.1 | 530.1 |
| P/E ratio | 30 x | 207 x | 62.4 x | 27.7 x | 35.2 x | 30.3 x | 25.8 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.97 x | 8.82 x | 13.6 x | 6.67 x | 9.13 x | 7.31 x | 6.53 x |
| EV / Revenue | 6.97 x | 8.82 x | 13.6 x | 6.67 x | 9.13 x | 7.31 x | 6.53 x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,485 | 12,270 | 12,342 | 12,566 | 12,606 | 12,664 | - |
| Reference price 2 | 23.38 | 22.80 | 46.21 | 28.29 | 47.47 | 41.86 | 41.86 |
| Announcement Date | 2/6/20 | 2/4/21 | 2/4/22 | 2/2/23 | 2/8/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 38.52 | 31.72 | 41.81 | 53.3 | 65.56 | 72.56 | 81.19 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | 8.647 | -0.7561 | 9.818 | 15.63 | 20.04 | 20.59 | 25.24 |
| Operating Margin | 22.45% | -2.38% | 23.48% | 29.32% | 30.56% | 28.38% | 31.08% |
| Earnings before Tax (EBT) 1 | 9.043 | -0.6169 | 9.836 | 16.18 | 21.74 | 22.65 | 26.54 |
| Net income 1 | 9.631 | 1.369 | 9.325 | 12.83 | 17.19 | 17.74 | 20.86 |
| Net margin | 25% | 4.32% | 22.3% | 24.06% | 26.22% | 24.44% | 25.69% |
| EPS 2 | 0.7800 | 0.1100 | 0.7400 | 1.020 | 1.350 | 1.380 | 1.620 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/4/21 | 2/4/22 | 2/2/23 | 2/8/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10.91 | 11.87 | 12.31 | 12.72 | 13.41 | 14.86 | 15.48 | 16.13 | 16.5 | 17.45 | 17.13 | 17.88 | 17.85 | 19.75 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 3.087 | 3.11 | 3.075 | 4.167 | 4.132 | 4.254 | 4.007 | 4.963 | 5.905 | 5.16 | 4.472 | 5.114 | 5.146 | 5.91 |
| Operating Margin | 28.3% | 26.19% | 24.98% | 32.75% | 30.82% | 28.62% | 25.89% | 30.77% | 35.78% | 29.57% | 26.1% | 28.6% | 28.83% | 29.92% |
| Earnings before Tax (EBT) 1 | 3.094 | 3.114 | 3.06 | 4.18 | 4.237 | 4.704 | 4.35 | 5.298 | 6.409 | 5.682 | 4.976 | 5.614 | 5.646 | 6.41 |
| Net income 1 | 2.576 | 3.893 | 2.487 | 3.241 | 3.427 | 3.673 | 3.406 | 4.18 | 5.067 | 4.54 | 3.846 | 4.408 | 4.406 | 5.026 |
| Net margin | 23.62% | 32.79% | 20.2% | 25.48% | 25.56% | 24.71% | 22.01% | 25.91% | 30.7% | 26.01% | 22.45% | 24.66% | 24.68% | 25.45% |
| EPS 2 | 0.2000 | 0.3100 | 0.2000 | 0.2600 | 0.2700 | 0.2900 | 0.2700 | 0.3300 | 0.4000 | 0.3600 | 0.3000 | 0.3450 | 0.3450 | 0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/29/21 | 2/4/22 | 4/29/22 | 7/29/22 | 11/3/22 | 2/2/23 | 5/4/23 | 8/3/23 | 11/3/23 | 2/8/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 2/6/20 | 2/4/21 | 2/4/22 | 2/2/23 | 2/8/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
41.86
USD
Average target price
62.5
USD
Spread / Average Target
+49.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.82% | 530M | |
| +73.17% | 12.38B | |
| -18.74% | 7.92B | |
| +16.15% | 7.2B | |
| +4.81% | 5.84B | |
| +5.99% | 5.07B | |
| +27.07% | 4.53B | |
| -21.67% | 3.88B | |
| -40.82% | 2.23B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- IRMD Stock
- Financials IRADIMED CORPORATION
